Edwards Lifesciences (NYSE:EW) Price Target Raised to $105.00 at Stifel Nicolaus

Edwards Lifesciences (NYSE:EW) had its price objective hoisted by equities research analysts at Stifel Nicolaus from $100.00 to $105.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Stifel Nicolaus’ price target suggests a potential upside of 22.69% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on the company. Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price for the company in a report on Monday, November 3rd. Jefferies Financial Group set a $98.00 price objective on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Citigroup reissued a “buy” rating and issued a $101.00 price objective (up previously from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Truist Financial set a $92.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, December 5th. Finally, Royal Bank Of Canada increased their price target on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average target price of $94.27.

Edwards Lifesciences Stock Up 1.7%

Edwards Lifesciences stock opened at $85.58 on Wednesday. The company’s 50-day moving average price is $84.94 and its two-hundred day moving average price is $80.19. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The stock has a market cap of $49.66 billion, a P/E ratio of 37.21, a P/E/G ratio of 3.42 and a beta of 0.95. Edwards Lifesciences has a twelve month low of $65.94 and a twelve month high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts expect that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $83.76, for a total value of $953,691.36. Following the sale, the vice president owned 38,970 shares in the company, valued at $3,264,127.20. This represents a 22.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 56,805 shares of company stock worth $4,775,995. Corporate insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the third quarter worth $25,000. Rosenberg Matthew Hamilton acquired a new position in Edwards Lifesciences during the 2nd quarter worth about $28,000. True Wealth Design LLC grew its position in shares of Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after buying an additional 259 shares during the last quarter. NewSquare Capital LLC increased its stake in shares of Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after buying an additional 134 shares during the period. Finally, Hantz Financial Services Inc. lifted its stake in shares of Edwards Lifesciences by 76.6% in the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after acquiring an additional 164 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.